Article
HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays.
AIDS research and human retroviruses - 10 Aug 2000
Robinson L H, Myers R E, Snowden B W, Tisdale M, Blair E D
Abstract excerpt
The recombinant virus assay (RVA) is a method for assessing the susceptibility of human immunodeficiency virus type 1 (HIV-1) plasma isolates to antiretroviral drugs. The RVA involves the production of viable virus in vitro by homologous recombination of RT-PCR products from plasma virus with a noninfectious reverse transcriptase (RT) or protease (PR)-deleted cloned HIV-1 provirus. In this study, we have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
